1
|
Compagnone D, Mandelli F, Ponzo M, Langella F, Cecchinato R, Damilano M, Redaelli A, Peretti GM, Vanni D, Berjano P. Complications in endoscopic spine surgery: a systematic review. Eur Spine J 2024; 33:401-408. [PMID: 37587257 DOI: 10.1007/s00586-023-07891-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 07/18/2023] [Accepted: 08/06/2023] [Indexed: 08/18/2023]
Abstract
PURPOSE This systematic review aims to investigate the complication rate of endoscopic spine surgeries, stratifying them by technique, district and kind of procedure performed. METHODS This study was conducted according to the PRISMA statement. The literature search was conducted in MEDLINE, CINAHL, EMBASE, Cochrane Register, OTseeker and ScienceDirect database. Types of studies included were observational studies (cohort studies, case-control studies and case series) and randomised or quasi-randomised clinical with human subjects. No restrictions on publication year were applied. Repeated articles, reviews, expert's comments, congress abstracts, technical notes and articles not in English were excluded. Several data were extracted from the articles. In particular, data of perioperative (≤ 3 months) and late (> 3 months) complications were collected and grouped according to: (1) surgical technique [uniportal full-endoscopic spine surgery (UESS) or unilateral biportal endoscopic spine surgery (UBESS)]; (2) spinal district treated [cervical, thoracic or lumbar] and (3) type of procedure [discectomy/decompression or fusion]. Complication analysis was performed in subgroups with at least 100 patients to have clinically meaningful statistical validity. RESULTS A total of 117 full-text articles were assessed for eligibility. Of the 117 records included, 95 focused their research on UESS (14 LOE V, 33 LOE IV, 43 LOE III and five LOE II) and 23 on UBESS (three LOE V, eight LOE IV, 10 LOE III and two LOE II). A total of 20,020 patients were extracted to investigate the incidence of different perioperative and late complications, 10,405 for UESS and 9615 for UBESS. CONCLUSION The present study summarises the complications reported in the literature for spinal endoscopic procedures. On the one hand, the most relevant described were perioperative complications (transient neurological deficit, dural tear and dysesthesia) that are especially meaningful for endoscopic discectomy and decompression. On the other hand, late complications, such as mechanical implant failure, are more common in endoscopic interbody fusion. LEVEL OF EVIDENCE I.
Collapse
Affiliation(s)
| | - Filippo Mandelli
- Department of Spine Surgery, University Hospital Basel, Basel, Switzerland
| | - Matteo Ponzo
- IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
| | | | | | | | | | - Giuseppe Maria Peretti
- IRCCS Ospedale Galeazzi Sant'Ambrogio, Milan, Italy
- Department of Biomedical Sciences for Health, University of Milan, 20133, Milan, Italy
| | | | | |
Collapse
|
2
|
Bellosta-López P, Mandelli F, Langella F, Brayda-Bruno M, Bassani R, Cecchinato R, Compagnone D, Giudici F, Luca A, Morselli C, Scaramuzzo L, Vanni D, Ponzo M, Berjano P. The influence of peri-operative depressive symptoms on medium-term spine surgery outcome: a prospective study. Eur Spine J 2023; 32:3394-3402. [PMID: 37552328 DOI: 10.1007/s00586-023-07875-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 07/18/2023] [Accepted: 07/27/2023] [Indexed: 08/09/2023]
Abstract
PURPOSE To investigate the role of depressive symptoms on clinical outcomes in patients undergoing spinal surgery up to 2-year follow-up. METHODS The study used data from an institutional spine surgery registry (January 2016, through March 2022) to identify patients (> 18 years) undergoing spine surgery. Patients with Oswestry Disability Index (ODI) < 20/100 at baseline or undergoing surgery on the cervical spine or for idiopathic spinal deformity and trauma patients were excluded. The patients were divided into two groups based on the pre-operative Mental Component Summary (MCS) score of the SF-36: depression group (MCS ≤ 35) or non-depression group (MCS > 35). The ODI and MCS scores trajectory were wined over the 24-month post-surgery between groups. Additionally, a secondary subgroup analysis was conducted comparing outcomes between those with depressive symptoms (persistent-depression subgroup) and those without depressive symptoms (never-depression subgroup) at 3 months after surgery. RESULTS A total of 2164 patients who underwent spine surgery were included. The pre-operative depression group reported higher ODI total scores and lower MCS than the pre-operative non-depression group at all time points (P < 0.001). The persistent-depression subgroup reported higher ODI total scores and lower MCS than the never-depression subgroup at all follow-ups (P < 0.001). CONCLUSION Functional disability and mental health status improve in patients with depression symptoms undergoing spinal surgery. Despite this improvement, they do not reach the values of non-depressed subjects. Over the 2-year follow-up time, patients with depression show a different trajectory of ODI and MCS. Caregivers should be aware of these results to counsel patients with depression symptoms.
Collapse
Affiliation(s)
- Pablo Bellosta-López
- Universidad San Jorge, Campus Universitario, Autov. A23 Km 299, 50830, Villanueva de Gállego, Zaragoza, Spain
| | - Filippo Mandelli
- Department of Spine Surgery, University Hospital Basel, Basel, Switzerland
| | | | | | | | | | | | | | - Andrea Luca
- IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | | | | | | | - Matteo Ponzo
- IRCCS Istituto Ortopedico Galeazzi, Milan, Italy
| | | |
Collapse
|
3
|
Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, Cascone I. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022 , 14, 4265. Cancers (Basel) 2022; 14:cancers14246160. [PMID: 36551754 PMCID: PMC9776549 DOI: 10.3390/cancers14246160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 11/23/2022] [Indexed: 12/15/2022] Open
Abstract
In the original publication [...].
Collapse
Affiliation(s)
- Matteo Ponzo
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Anais Debesset
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mélissande Cossutta
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mounira Chalabi-Dchar
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Claire Houppe
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Caroline Pilon
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Alba Nicolas-Boluda
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
| | - Sylvain Meunier
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Fabio Raineri
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Allan Thiolat
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Rémy Nicolle
- Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, F-75013 Paris, France
| | - Federica Maione
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Serena Brundu
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Carina Florina Cojocaru
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Philippe Bouvet
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
- Ecole Normale Supérieure de Lyon, University of Lyon, F-69342 Lyon, France
| | - Corinne Bousquet
- UMR INSERM-1037, Cancer Research Center of Toulouse (CRCT), Toulouse University III, F-31037 Toulouse, France
| | - Florence Gazeau
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Christophe Tournigand
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Service d’Oncologie Médicale, Groupe Hospitalo-Universitaire Chenevier Mondor, F-94010 Créteil, France
| | - José Courty
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Enrico Giraudo
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - José L. Cohen
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Ilaria Cascone
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
- Correspondence: ; Tel.: +33-149-813-765
| |
Collapse
|
4
|
Redaelli A, Panico M, Cecchinato R, Damilano M, Vanni D, Ponzo M, Galbusera F, Langella F. Oblique, unilateral, or bilateral rods configurations for single-level interbody fusion and posterior spinal fixation: a finite element study. Turk Neurosurg 2022. [DOI: 10.5137/1019-5149.jtn.42502-22.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
5
|
Bonanni A, Pedicino D, Vinci R, D'Aiello A, Ponzo M, Ciampi P, Pisano E, Canonico F, Di Sario M, Conte C, Cribari F, Grimaldi MC, Severino A, Crea F, Liuzzo G. Takotsubo syndrome: a way to reach a straightforward diagnosis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1392] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background/Introduction
Acute stress-induced cardiomyopathy, also known as Takotsubo Syndrome (TTS), was originally classified as a benign disease. Nowadays, this assumption has changed, especially in its long-term outcome, due to TTS clinical presentation, that often mirrors the acute myocardial infarction (MI) phenotype. Current knowledge already delineate clinical features distinctive of TTS and MI patients, however, diagnosis requires multiple, expansive, and invasive medical examinations. Moreover, concerning the biological panorama, very slight is known and the lack of a tailored therapy is resented. Therefore, a biological profile for this clinical category could provide easier and less invasive diagnostic tools, leading edge towards novel therapeutic pathways.
Purpose
The aim of the study is to perform a biological profile of the TTS group compared to the ST Segment Elevation Myocardial Infarction (STEMI) in order to explore the molecular peculiarities attendant the pathophysiologic mechanisms.
Methods
We performed a gene expression array on two groups of pooled cDNA from peripheral blood mononuclear cells, from TTS (n=11) and STEMI (n=19) patients. We conducted gene expression validations for each enrolled patient through qPCR.
Results
Our preliminary data displayed several differences in gene expression levels of a grand number of cell adhesion signaling molecule between the two groups. As shown in figure 1, three gene were more expressed in TTS group: Nitric Oxide Synthase 3, also known as endothelial NOS (NOS3; p=0.002), Superoxide dismutase 1 (SOD1; p=0.03) and transferrin receptor (TFRC; p=0.005). Meanwhile, five gene displayed a higher expression in STEMI patients compared to TTS: phospholipase A2 Group 7 (PLA2G7; p=0.04), Galectin 8 (LGALS8; p=0.02), Intercellular Adhesion Molecule 1 (ICAM1; p=0.002), Hyaluronidase 2 (HYAL2; p=0.01) and Hyaluronan Receptor (CD44; p=0.0002).
Conclusions
The earliest results of this study led us to focus on fewer genes related to endothelial and oxidative stress pathways. TTS is habitually triggered by intense emotional or physical stress. Indeed, our results showed how TTS patients present higher expression of NOS3, SOD1 and TFRC, all components involved in the oxidative stress pathways. In STEMI patients, top expressed genes, such as HYAL2, CD44 and ICAM1, are all associated with extracellular matrix turnover, likely due to the presence of a stenotic plaque and the consequent endothelial derangement. The uncovering of diagnostic biomarkers in TTS might improve the early, non-invasive, stratification of this group of patients, thus facilitating novel and personalized therapeutics design.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The present study was supported by the Italian National Project Grant PRIN 2017.
Collapse
Affiliation(s)
- A Bonanni
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - D Pedicino
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - R Vinci
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A D'Aiello
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - M Ponzo
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - P Ciampi
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - E Pisano
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - F Canonico
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - M Di Sario
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - C Conte
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - F Cribari
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - M C Grimaldi
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A Severino
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - F Crea
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - G Liuzzo
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| |
Collapse
|
6
|
Raineri F, Bourgoin-Voillard S, Cossutta M, Habert D, Ponzo M, Houppe C, Vallée B, Boniotto M, Chalabi-Dchar M, Bouvet P, Couvelard A, Cros J, Debesset A, Cohen JL, Courty J, Cascone I. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021; 13:cancers13122986. [PMID: 34203710 PMCID: PMC8232280 DOI: 10.3390/cancers13122986] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 06/08/2021] [Accepted: 06/10/2021] [Indexed: 01/03/2023] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and resistant cancer with no available effective therapy. We have previously demonstrated that nucleolin targeting by N6L impairs tumor growth and normalizes tumor vessels in PDAC mouse models. Here, we investigated new pathways that are regulated by nucleolin in PDAC. We found that N6L and nucleolin interact with β-catenin. We found that the Wnt/β-catenin pathway is activated in PDAC and is necessary for tumor-derived 3D growth. N6L and nucleolin loss of function induced by siRNA inhibited Wnt pathway activation by preventing β-catenin stabilization in PDAC cells. N6L also inhibited the growth and the activation of the Wnt/β-catenin pathway in vivo in mice and in 3D cultures derived from MIA PaCa2 tumors. On the other hand, nucleolin overexpression increased β-catenin stabilization. In conclusion, in this study, we identified β-catenin as a new nucleolin interactor and suggest that the Wnt/β-catenin pathway could be a new target of the nucleolin antagonist N6L in PDAC.
Collapse
Affiliation(s)
- Fabio Raineri
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Sandrine Bourgoin-Voillard
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- University of Grenoble Alpes, CNRS, Grenoble INP, Inserm U1055, LBFA and BEeSy, PROMETHEE Proteomic Platform, 38400 Saint-Martin d’Heres, France
- University of Grenoble Alpes, CNRS, Grenoble INP, TIMC, PROMETHEE Proteomic Platform, 38000 Grenoble, France
- CHU Grenoble Alpes, Institut de Biologie et de Pathologie, 38043 Grenoble, France
| | - Mélissande Cossutta
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - Damien Habert
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Matteo Ponzo
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Claire Houppe
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Benoît Vallée
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Michele Boniotto
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Mounira Chalabi-Dchar
- Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France; (M.C.-D.); (P.B.)
| | - Philippe Bouvet
- Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France; (M.C.-D.); (P.B.)
- University of Lyon, Ecole Normale Supérieure de Lyon, 69342 Lyon, France
| | - Anne Couvelard
- Département de Pathologie, Hôpital Bichat APHP DHU UNITY, 75018 Paris, France; (A.C.); (J.C.)
| | - Jerome Cros
- Département de Pathologie, Hôpital Bichat APHP DHU UNITY, 75018 Paris, France; (A.C.); (J.C.)
| | - Anais Debesset
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - José L. Cohen
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - José Courty
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - Ilaria Cascone
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
- Correspondence: ; Tel.: +33-149-813-765
| |
Collapse
|
7
|
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife 2021; 10:58688. [PMID: 34106045 PMCID: PMC8203293 DOI: 10.7554/elife.58688] [Citation(s) in RCA: 105] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 06/05/2021] [Indexed: 12/17/2022] Open
Abstract
Only a fraction of cancer patients benefits from immune checkpoint inhibitors. This may be partly due to the dense extracellular matrix (ECM) that forms a barrier for T cells. Comparing five preclinical mouse tumor models with heterogeneous tumor microenvironments, we aimed to relate the rate of tumor stiffening with the remodeling of ECM architecture and to determine how these features affect intratumoral T cell migration. An ECM-targeted strategy, based on the inhibition of lysyl oxidase, was used. In vivo stiffness measurements were found to be strongly correlated with tumor growth and ECM crosslinking but negatively correlated with T cell migration. Interfering with collagen stabilization reduces ECM content and tumor stiffness leading to improved T cell migration and increased efficacy of anti-PD-1 blockade. This study highlights the rationale of mechanical characterizations in solid tumors to understand resistance to immunotherapy and of combining treatment strategies targeting the ECM with anti-PD-1 therapy.
Collapse
Affiliation(s)
- Alba Nicolas-Boluda
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Laboratoire Matière et Systèmes Complexes (MSC), CNRS, Université de Paris, Paris, France
| | - Javier Vaquero
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France.,TGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,LPP (Laboratoire de physique des plasmas, UMR 7648), Sorbonne Université, Centre national de la recherche scientifique (CNRS), Ecole Polytechnique, Paris, France.,Oncology Program, CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Barcelona, Spain
| | - Lene Vimeux
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Thomas Guilbert
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France
| | - Sarah Barrin
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Chahrazade Kantari-Mimoun
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Matteo Ponzo
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - Gilles Renault
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France
| | - Piotr Deptula
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland
| | - Katarzyna Pogoda
- Institute of Nuclear Physics, Polish Academy of Sciences, Kraków, Poland
| | - Robert Bucki
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland
| | - Ilaria Cascone
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - José Courty
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - Laura Fouassier
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France
| | - Florence Gazeau
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS, Université de Paris, Paris, France
| | - Emmanuel Donnadieu
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| |
Collapse
|
8
|
Pedicino D, Angelini A, Russo G, D"aiello A, Rocco E, Ciampi P, Ponzo M, Graziani F, Locorotondo G, Sanna T, Rebuzzi AG, Lombardo A, Massetti M, Liuzzo G, Crea F. Non invasive ventilation and right ventricle function in cardiogenic pulmonary edema: an echocardiographic perspective to select the "right" ventilatory support. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
High-flow nasal cannulae oxygen therapy (HFNCOT) represents a better tolerated alternative to non-invasive pressure support ventilation (NIPSV) for acute cardiogenic pulmonary edema (ACPE) treatment. However, there are still few data on the effect of HFNCOT on cardiac function and hemodynamic.
Purpose
To assess and compare the effects of NIPSV and HFNCOT in ACPE setting on right ventricular (RV) systolic function and on indices of cardiac filling and output, as measured by echocardiography.
Methods
This is a cross-over controlled study, enrolling 15 consecutive patients admitted to our Cardiovascular Intensive Care Unit for ACPE and hypoxaemic, normo/hypocapnic acute respiratory failure, with P/F ratio < 200. Each patient received NIPSV, followed by HFNCOT. Full echocardiographic assessment and blood gas analysis (BGA) were performed 40 minutes from onset of each ventilation modality, respectively before NIPSV to HFNCOT switch and before HFNCOT interruption. In particular, RV function parameters, together with RV and atrial strain, were prospectively collected.
Results
In spite of not significant changes in BGA, RV function was significantly improved under HFNCOT, as compared to NIPSV, as assessed by the following parameters: tricuspid annular plane excursion (TAPSE) (P = 0.001), RV S’ wave (P = 0.007), RV fractional area change (RVFAC) (P = 0.006). Strain analysis confirmed the significant improvement in RV function, with free wall global longitudinal strain (GLS) and free wall and septum GLS significantly higher under HFNCOT, as compared to NIPSV (-21% vs -18% P < 0.001, and -15% vs -19% P = 0.008, respectively,), and a significant increase in right atrial positive longitudinal strain (P < 0.001).
Conclusions
NIPSV significantly affect RV function making more complex the management of patients presenting with ACPE. In this setting, HFNCOT represents a valuable alternative, providing similar respiratory outcomes while preserving good right ventricle performance.
Collapse
Affiliation(s)
- D Pedicino
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy
| | - A Angelini
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - G Russo
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - A D"aiello
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - E Rocco
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - P Ciampi
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - M Ponzo
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - F Graziani
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy
| | - G Locorotondo
- Fondazione Policlinico Universitario A. Gemelli IRCSS, Rome, Italy
| | - T Sanna
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - AG Rebuzzi
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - A Lombardo
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - M Massetti
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - G Liuzzo
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| | - F Crea
- Catholic University of the Sacred Heart, Institute of Cardiology, Rome, Italy
| |
Collapse
|
9
|
Samain R, Brunel A, Douché T, Fanjul M, Cassant-Sourdy S, Rochotte J, Cros J, Neuzillet C, Raffenne J, Duluc C, Perraud A, Nigri J, Gigoux V, Bieche I, Ponzo M, Carpentier G, Cascone I, Tomasini R, Schmid HA, Mathonnet M, Nicolle R, Bousquet MP, Martineau Y, Pyronnet S, Jean C, Bousquet C. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Cell Mol Gastroenterol Hepatol 2021; 11:1405-1436. [PMID: 33482394 PMCID: PMC8024982 DOI: 10.1016/j.jcmgh.2021.01.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Revised: 01/08/2021] [Accepted: 01/11/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS Cancer-associated fibroblasts (CAFs) from pancreatic adenocarcinoma (PDA) present high protein synthesis rates. CAFs express the G-protein-coupled somatostatin receptor sst1. The sst1 agonist SOM230 blocks CAF protumoral features in vitro and in immunocompromised mice. We have explored here the therapeutic potential of SOM230, and underlying mechanisms, in immunocompetent models of murine PDA mimicking the heavy fibrotic and immunosuppressive stroma observed in patient tumors. METHODS Large-scale mass spectrometry analyses were performed on media conditioned from 9 patient PDA-derived CAF primary cultures. Spontaneous transgenic and experimental (orthotopic co-graft of tumor cells plus CAFs) PDA-bearing mice were longitudinally ultrasound-monitored for tumor and metastatic progression. Histopathology and flow cytometry analyses were performed on primary tumors and metastases. Stromal signatures were functionally validated through bioinformatics using several published, and 1 original, PDA database. RESULTS Proteomics on the CAF secretome showed that SOM230 controls stromal activities including inflammatory responses. Among the identified secreted proteins, we validated that colony-stimulating factor 1 (CSF-1) (a macrophage growth factor) was reduced by SOM230 in the tumor and plasma of PDA-harboring mice, alongside intratumor stromal normalization (reduced CAF and macrophage activities), and dramatic metastasis reduction. In transgenic mice, these SOM230 benefits alleviate the chemotherapy-induced (gemcitabine) immunosuppressive stroma reshaping. Mechanistically, SOM230 acts in vivo on CAFs through sst1 to disrupt prometastatic CAF production of CSF-1 and cross-talk with macrophages. We found that in patients, stromal CSF-1 was associated with aggressive PDA forms. CONCLUSIONS We propose SOM230 as an antimetastatic therapy in PDA for its capacity to remodel the fibrotic and immunosuppressive myeloid stroma. This pharmacotherapy should benefit PDA patients treated with chemotherapies.
Collapse
Affiliation(s)
- Rémi Samain
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Alexia Brunel
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Thibault Douché
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Marjorie Fanjul
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Stéphanie Cassant-Sourdy
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Julia Rochotte
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Jérôme Cros
- Department of Pathology, Beaujon-Bichat University Hospital–Paris Diderot University, Clichy, France
| | - Cindy Neuzillet
- Medical Oncology Department, Curie Institute, Versailles Saint-Quentin University, Saint Cloud, France
| | - Jérôme Raffenne
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Camille Duluc
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Aurélie Perraud
- Equipe d'Accueil EA 3842 Laboratory, Medicine and Pharmacy Faculties, University of Limoges, Limoges, France
| | - Jérémy Nigri
- INSERM U1068/UMR 7258 CNRS, Cancer Research Center of Marseille, Marseille, France
| | - Véronique Gigoux
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Ivan Bieche
- Department of Genetics, Institut Curie, Paris Descartes University, Paris, France
| | - Matteo Ponzo
- Growth, Reparation and Tissue Regeneration Laboratory, Equipe de Recherche Labellisée ERL-CNRS 9215, University of Paris-Est, Créteil, France
| | - Gilles Carpentier
- Growth, Reparation and Tissue Regeneration Laboratory, Equipe de Recherche Labellisée ERL-CNRS 9215, University of Paris-Est, Créteil, France
| | - Ilaria Cascone
- Growth, Reparation and Tissue Regeneration Laboratory, Equipe de Recherche Labellisée ERL-CNRS 9215, University of Paris-Est, Créteil, France
| | - Richard Tomasini
- INSERM U1068/UMR 7258 CNRS, Cancer Research Center of Marseille, Marseille, France
| | | | - Muriel Mathonnet
- Equipe d'Accueil EA 3842 Laboratory, Medicine and Pharmacy Faculties, University of Limoges, Limoges, France
| | - Rémy Nicolle
- Programme Cartes d’Identité des Tumeurs, Ligue Nationale Contre Le Cancer, Paris, France
| | - Marie-Pierre Bousquet
- Institute for Pharmacology and Structural Biology, University of Toulouse, Toulouse, France
| | - Yvan Martineau
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Stéphane Pyronnet
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Christine Jean
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France
| | - Corinne Bousquet
- Centre de Recherches en Cancérologie de Toulouse (CRCT), Université de Toulouse, INSERM Unité Mixte de Recherche UMR-1037, CNRS Equipe de Recherche Labellisée ERL5294, Equipe de Recherche Labellisée "Ligue Contre le Cancer" & "LabEx Toucan", Toulouse, France,Correspondence Address correspondence to: Corinne Bousquet, VMD, PhD, INSERM U1037, Cancer Research Center of Toulouse, 2 Avenue Hubert Curien, CS53717, 31037 Toulouse Cedex 1, France. fax: (33) (0) 56131-9752.
| |
Collapse
|
10
|
Pisano E, Severino A, Bugli F, Pedicino D, Paroni Sterbini F, Martini C, Vinci R, Canonico F, Bonanni A, D'Aiello A, Ciampi P, Ponzo M, Sanguinetti M, Crea F, Liuzzo G. Plaque instability in acute coronary syndromes: a possible pathogenic role of gut microbial communities. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The imbalance between protective and harmful bacteria in the microbial communities leads to a non-physiological condition, known as “dysbiosis”. In the last decade, several studies have suggested that gut microbiota can contribute to the development and progression of various disease including cardiovascular disease through metabolism-mediated pathways. The production and the release of bacterial metabolites, including Trimethylamine N-oxide (TMAO), can affect host health acting to distant organs.
Purpose
The aim of the present study was to explore the gut microbiota and the levels of TMAO in patients with stable angina (SA) and acute coronary syndrome (ACS) with or without elevation of the ST segment, respectively STEMI and NSTEMI, and in control subjects.
Methods
Feces were obtained from ACS (n=31) and SA (n=23) patients and controls (n=24). Genomic DNA was isolated using the QIamp DNA Stool Mini Kit. Samples were subjected to 16S rRNA gene V3–V4 region sequencing by an Illumina MiSeq TM platform. A combination of software packages QIIME and VSEARCH was used to generate a biological observation matrix (BIOM) at different taxonomic levels (from phylum to genus). The BIOM was analysed using the Web-based program MicrobiomeAnalyst. β-diversity between groups was obtained by weighted UniFrac distance metric analysis. Serum TMAO levels were measured with a UPLC-MS/MS mass spectrometry in SA and ACS patients.
Results
β-diversity analysis showed a different bacterial composition in SA and ACS patients and controls ([PERMANOVA] F-value: 1.9706; R-squared: 0.050567; p-value <0.018) (Figure 1A). In particular, analysis between the three groups revealed a significant enrichment of Streptococcus genus in ACS patients (Kruskas Wallis test; p=0.0085) (Figure 1B). Controls and ACS revealed a similar gut microbial composition ([PERMANOVA] F-value: 0.7591; R-squared: 0.014388; p-value <0.61) (Figure 2A); in contrast, controls and SA showed separate clusters according to relative differences in taxonomic composition ([PERMANOVA] F-value: 3.0498; R-squared: 0.064821 p-value <0.006) (Figure 2B). Finally, β-diversity analysis in SA and ACS revealed different microbial communities in the two groups [PERMANOVA] F-value: 2.5103; R-squared: 0.046051; p-value <0.025) (Figure 2C) that could partially explain the severity progression of cardiovascular disease. Serum TMAO levels were higher in STEMI (n=14) as compared to SA and to NSTEMI (n=16) (respectively p=0.016 and p=0.028) (Figure 3).
Conclusion
These results, taken together, suggest that gut microbiota and its derived metabolites might play an essential role in the progression of atherosclerosis and in coronary plaque instability.
Funding Acknowledgement
Type of funding source: Other. Main funding source(s): Linea D1 Università Cattolica del Sacro Cuore
Collapse
Affiliation(s)
- E Pisano
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| | - A Severino
- Catholic University of the Sacred Heart, Rome, Italy
| | - F Bugli
- Catholic University of the Sacred Heart, Rome, Italy
| | - D Pedicino
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| | - F Paroni Sterbini
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| | - C Martini
- Catholic University of the Sacred Heart, Rome, Italy
| | - R Vinci
- Catholic University of the Sacred Heart, Rome, Italy
| | - F Canonico
- Catholic University of the Sacred Heart, Rome, Italy
| | - A Bonanni
- Catholic University of the Sacred Heart, Rome, Italy
| | - A D'Aiello
- Polyclinic Agostino Gemelli IRCCS, Rome, Italy
| | - P Ciampi
- Polyclinic Agostino Gemelli IRCCS, Rome, Italy
| | - M Ponzo
- Polyclinic Agostino Gemelli IRCCS, Rome, Italy
| | - M Sanguinetti
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| | - F Crea
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| | - G Liuzzo
- Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Departement of Cardiovascular Science, Rome, Italy
| |
Collapse
|
11
|
Canonico F, Vinci R, Pedicino D, Pisano E, Ciampi P, Bonanni A, Ponzo M, D'Aiello A, Di Sario M, Severino A, D'Amario D, Niccoli G, Biasucci L, Crea F, Liuzzo G. Meta-inflammation in monocytes of patients with Acute Coronary Syndrome. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Several studies suggest that an alteration of monocyte metabolism might be implicated in inflammatory diseases. Enhanced glycolysis might be a hallmark of pro-inflammatory monocyte subsets. Improved glycolysis enables the immune cells to generate sufficient ATP and biosynthetic intermediates to carry out its particular effector functions. For macrophages this includes phagocytosis and inflammatory cytokine production. Pyruvate Kinase isozyme M2 (PKM-2) catalyzes the final step of glycolysis producing pyruvate and ATP. Latest studies have shown that a member of Jumonji family (JMJD8) acts as a positive regulator in TNF-induced NF-kB signaling leading to pro-inflammatory pathways in macrophages and is involved in angiogenesis and cellular metabolism through interacting with PKM-2 in endothelial cells.
Purpose
The aims of the study are to assess the expression of the glycolytic key enzyme PKM-2 in CD14+ monocytes obtained from patients with non-ST-elevation myocardial infarction (NSTEMI) or with stable angina (SA). Furthermore, the expression of JMJD8 was evaluated.
Methods
30 patients with NSTEMI and 30 patients with SA were enrolled. Peripheral blood mononuclear cells were obtained from whole blood samples. For cytoplasmatic protein identification, cells were fixed and permeabilized and then incubated with fluorochrome-conjugated mAbs anti-CD14, anti-PKM-2 and anti-JMJD8. For analysis we used Two-tailed Mann-Whitney non parametric Comparison test.
Results
CD14+ monocytes from NSTEMI patients showed reduced expression of the key glycolytic enzyme PKM-2 as compared to CD14+ monocytes from SA patients (p=0.02) (Figure 1). JMJD8 expression in NSTEMI patients is increased compared with SA patients (p=0.02) (Figure 2).
Conclusion
This study introduces a role for immune-metabolism in the immunity dysregulation described in ACS patients and provides novel insights into the mechanisms responsible for coronary instability. Taking their potential interaction into account, our data suggest that in acute setting glycolysis key enzyme PKM2 expression is downregulated. Besides, JMJD8 protein levels increase in NSTEMI patients acting as potential limiting factor of PKM2 function. Moreover, our data propose the potential roles of immune-metabolism to detect novel therapeutic targets, associated with an accurate patient stratification based on immune-metabolic profiles, for prevention and treatment of atherosclerosis, in the perspective of a personalized medicine approach.
Funding Acknowledgement
Type of funding source: Private hospital(s). Main funding source(s): Fondazione Policlinico A. Gemelli
Collapse
Affiliation(s)
- F Canonico
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - R Vinci
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - D Pedicino
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - E Pisano
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - P Ciampi
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - A Bonanni
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - M Ponzo
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - A D'Aiello
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - M Di Sario
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - A Severino
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - D D'Amario
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - G Niccoli
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - L.M Biasucci
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - F Crea
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| | - G Liuzzo
- Fondazione Policlinico Universitario Gemelli IRCCS, Catholic University, Rome, Italy
| |
Collapse
|
12
|
Cossutta M, Darche M, Carpentier G, Houppe C, Ponzo M, Raineri F, Vallée B, Gilles ME, Villain D, Picard E, Casari C, Denis C, Paques M, Courty J, Cascone I. Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis. Arterioscler Thromb Vasc Biol 2019; 39:1843-1858. [PMID: 31315435 DOI: 10.1161/atvbaha.119.313021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Objective Weibel-Palade bodies (WPBs) are endothelial cell (EC)-specific organelles formed by vWF (von Willebrand factor) polymerization and that contain the proangiogenic factor Ang-2 (angiopoietin-2). WPB exocytosis has been shown to be implicated for vascular repair and inflammatory responses. Here, we investigate the role of WPBs during angiogenesis and vessel stabilization. Approach and Results WPB density in ECs decreased at the angiogenic front of retinal vascular network during development and neovascularization compared with stable vessels. In vitro, VEGF (vascular endothelial growth factor) induced a VEGFR-2 (vascular endothelial growth factor receptor-2)-dependent exocytosis of WPBs that contain Ang-2 and consequently the secretion of vWF and Ang-2. Blocking VEGF-dependant WPB exocytosis and Ang-2 secretion promoted pericyte migration toward ECs. Pericyte migration was inhibited by adding recombinant Ang-2 or by silencing Ang-1 (angiopoietin-1) or Tie2 (angiopoietin-1 receptor) in pericytes. Consistently, in vivo anti-VEGF treatment induced accumulation of WPBs in retinal vessels because of the inhibition of WPB exocytosis and promoted the increase of pericyte coverage of retinal vessels during angiogenesis. In tumor angiogenesis, depletion of WPBs in vWF knockout tumor-bearing mice promoted an increase of tumor angiogenesis and a decrease of pericyte coverage of tumor vessels. By another approach, normalized tumor vessels had higher WPB density. Conclusions We demonstrate that WPB exocytosis and Ang-2 secretion are regulated during angiogenesis to limit pericyte coverage of remodeling vessels by disrupting Ang-1/Tie2 autocrine signaling in pericytes.
Collapse
Affiliation(s)
- Mélissande Cossutta
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Marie Darche
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Gilles Carpentier
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Claire Houppe
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Matteo Ponzo
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.).,Quinze Vingts National Ophthalmology Hospital, Paris, France (M.P.)
| | - Fabio Raineri
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Benoit Vallée
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Maud-Emmanuelle Gilles
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Delphine Villain
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Emilie Picard
- Inserm, U1138, Team 17, Physiopathology of Ocular Diseases to Clinical Development, University of Paris Descartes Sorbonne Paris Cité, Cordeliers Research Center, France (E.P.)
| | - Caterina Casari
- Inserm, UMR S1176, Paris-Sud University, Paris-Saclay University, Le Kremlin-Bicêtre, France (C.C., C.D.)
| | - Cécile Denis
- Inserm, UMR S1176, Paris-Sud University, Paris-Saclay University, Le Kremlin-Bicêtre, France (C.C., C.D.)
| | - Michel Paques
- Department of Therapeutics, Sorbonne University, INSERM, CNRS, Vision Institute, Paris, France (M.P.)
| | - José Courty
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| | - Ilaria Cascone
- From the CRRET laboratory, CNRS ERL 9215, University of Paris-Est Créteil (UPEC), France (M.C., M.D., G.C., C.H., M.P., F.R., B.V., M.-E.G., D.V., J.C., I.C.)
| |
Collapse
|
13
|
Vinci R, Pedicino D, Pisano E, Flego D, Giglio AF, Trotta F, Lucci C, Ruggio A, Ponzo M, D'Aiello A, Canonico F, Severino A, Biasucci LM, Liuzzo G, Crea F. P1692Increased expression of CD31 on platelets from patients with Non-ST segment Elevation Myocardial Infarction and its role in platelets-monocytes interaction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1692] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- R Vinci
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - D Pedicino
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - E Pisano
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - D Flego
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - A F Giglio
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - F Trotta
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - C Lucci
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - A Ruggio
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - M Ponzo
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - A D'Aiello
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - F Canonico
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - A Severino
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - L M Biasucci
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - G Liuzzo
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| | - F Crea
- Catholic University of the Sacred Heart, Department of Cardiovascular and Thoracic Sciences, Rome, Italy
| |
Collapse
|
14
|
Papini E, Pagano A, Panunzi C, Ponzo M, Rovagna MC, Picardi R. [Behavior of the principal serum enzyme activities in the course of hepatobiliary diseases]. Recenti Prog Med 1978; 65:277-85. [PMID: 30121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
15
|
Ponzo M, Rossi Z, Picardi R, De Filippo MG. Cytochemical aspects of the zymogen in rat pancreas electron microscopic study. Ann Histochim 1973; 18:123-9. [PMID: 4786517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
16
|
Ponzo M. Obituary to Frederico Kiesow, 1858-1941. Psychol Rev 1941. [DOI: 10.1037/h0056214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
17
|
Jenkins W, Kiesow F, Ponzo M. Ueber einige Beruhrungstauschungen. The American Journal of Psychology 1908. [DOI: 10.2307/1413411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|